| Menorrhagia
Natazia vs Myfembree
Side-by-side clinical, coverage, and cost comparison for menorrhagia.Deep comparison between: Natazia vs Myfembree with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMyfembree has a higher rate of injection site reactions vs Natazia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Myfembree but not Natazia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Natazia
Myfembree
At A Glance
Oral
Daily
Combined oral contraceptive
Oral
Daily
GnRH receptor antagonist
Indications
- Menorrhagia
- Uterine Fibroids
- Menorrhagia
- Endometriosis
Dosing
Menorrhagia One tablet daily by mouth at the same time every day, taken in the order directed on the blister pack for a 28-day sequential regimen; do not skip or delay intake by more than 12 hours.
Uterine Fibroids, Menorrhagia One tablet orally once daily; start no later than seven days after menses onset; maximum treatment duration 24 months.
Endometriosis One tablet orally once daily; start no later than seven days after menses onset; maximum treatment duration 24 months.
Contraindications
- Smoking if over age 35
- Deep vein thrombosis or pulmonary embolism, current or past
- Cerebrovascular disease
- Coronary artery disease
- Thrombogenic valvular or thrombogenic rhythm diseases of the heart (e.g., subacute bacterial endocarditis with valvular disease, or atrial fibrillation)
- Inherited or acquired hypercoagulopathies
- Uncontrolled hypertension
- Diabetes mellitus with vascular disease
- Headaches with focal neurological symptoms, or migraine headaches with or without aura if over age 35
- Undiagnosed abnormal uterine bleeding
- Current or history of breast cancer which may be hormone sensitive
- Liver tumors (benign or malignant) or liver disease
- High risk of arterial, venous thrombotic, or thromboembolic disorders, including women over 35 who smoke, history of DVT or PE, vascular disease, thrombogenic valvular or rhythm disease, hypercoagulopathy, uncontrolled hypertension, or migraine headaches with aura if over 35
- Pregnancy
- Known osteoporosis
- Current or history of breast cancer or other hormone-sensitive malignancy, or increased risk for hormone-sensitive malignancies
- Known hepatic impairment or disease
- Undiagnosed abnormal uterine bleeding
- Known anaphylactic reaction, angioedema, or hypersensitivity to MYFEMBREE or any of its components
Adverse Reactions
Most common (>=2%) Headache (including migraines), breast pain or tenderness, menstrual disorders, nausea or vomiting, acne, mood changes, increased weight
Serious Myocardial infarction, ruptured ovarian cyst, deep vein thrombosis, focal nodular hyperplasia of the liver, uterine leiomyoma, acute cholecystitis, chronic acalculous cholecystitis
Postmarketing Venous and arterial thromboembolic events, hypertension, gallbladder disease, hepatitis, hypersensitivity, fluid retention, hypertriglyceridemia, dizziness, chloasma, angioedema, erythema nodosum, erythema multiforme, gastrointestinal symptoms, vulvovaginal candidiasis
Most common (>=3%) Headache, vasomotor symptoms, mood disorders, abnormal uterine bleeding, nausea, toothache, back pain, decreased sexual desire and arousal, arthralgia, fatigue, dizziness, alopecia, libido decreased
Serious Thromboembolic disorders and vascular events, bone loss, suicidal ideation and mood disorders, hepatic impairment and transaminase elevations, elevated blood pressure, uterine fibroid prolapse or expulsion, hypersensitivity reactions
Postmarketing Anaphylactoid reaction, drug eruption, angioedema, urticaria, uterine leiomyoma degeneration
Pharmacology
Combined oral contraceptive (COC) that lowers the risk of pregnancy primarily by suppressing ovulation; contains estradiol valerate, a synthetic prodrug of 17beta-estradiol, and dienogest, a progestin with properties of both 19-nortestosterone and progesterone derivatives.
GnRH receptor antagonist combination; relugolix competitively binds pituitary GnRH receptors to suppress LH and FSH, reducing ovarian estradiol and progesterone, while co-formulated estradiol mitigates bone loss and norethindrone acetate provides endometrial protection against unopposed estrogen.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Natazia
- Covered on 5 commercial plans
- PA (2/12) · Step Therapy (0/12) · Qty limit (0/12)
Myfembree
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (6/12) · Qty limit (10/12)
UnitedHealthcare
Natazia
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Myfembree
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Natazia
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Myfembree
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Natazia.
$5/momo
Myfembree Copay Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NataziaView full Natazia profile
MyfembreeView full Myfembree profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.